Nivolumab in advanced lung cancer: Indication of major added benefit
(Institute for Quality and Efficiency in Health Care) Patients with advanced nonsquamous NSCLC who have already undergone chemotherapy survive longer with the drug than with docetaxel. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - August 18, 2016 Category: Global & Universal Source Type: news
AstraZeneca Provides Update On Phase III Trial Of Selumetinib In Non-Small Cell Lung Cancer
BOULDER, Colo., Aug. 9, 2016 -- (Healthcare Sales & Marketing Network) -- AstraZeneca (LON/STO/NYSE: AZN) today announced results from the Phase III SELECT-1 trial of the MEK 1/2 inhibitor, selumetinib, in combination with docetaxel chemotherapy as 2nd-li... Biopharmaceuticals, Oncology AstraZeneca, Array BioPharma, selumetinib, NSCLC, KRAS (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - August 9, 2016 Category: Pharmaceuticals Source Type: news
NICE recommends VARGATEF < sup > ® < /sup > (nintedanib*) in combination with docetaxel as an option for patients with non-small cell lung cancer of adenocarcinoma histology within its licensed indication
(Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - July 25, 2016 Category: Research Source Type: news
VARGATEF < sup > ® < /sup > plus docetaxel significantly reduced tumour burden in lung cancer patients with advanced adenocarcinoma compared to docetaxel alone
(Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - July 25, 2016 Category: Research Source Type: news
Nivolumab cost-effectiveness improves by selecting non-squamous NSCLC PD-L1+ patients
(International Association for the Study of Lung Cancer) Nivolumab (NIV), a checkpoint inhibitor approved for all squamous and non-squamous non-small cell lung cancer (NSCLC) patients in 2015, is not cost-effective when compared to treatment with docetaxel (DOC), chemotherapy medication. However, a Swiss analysis showed the cost-effectiveness of NIV is improved when patients are treated with NIV based on PD-L1 positivity (PD-L1+), or if there is a reduction in dose or drug price. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - July 13, 2016 Category: Global & Universal Source Type: news
ASCO: Intermittent Docetaxel May be Option in mCRPC (CME/CE)
(MedPage Today) -- Chemo breaks well tolerated, with good 1-year survival (Source: MedPage Today Meeting Coverage)
Source: MedPage Today Meeting Coverage - June 9, 2016 Category: Journals (General) Source Type: news
ASCO: Docetaxel Still King in Chemo-Naive mCRPC Patients (CME/CE)
(MedPage Today) -- Cabazitaxel remains a second-line therapy after docetaxel (Source: MedPage Today Meeting Coverage)
Source: MedPage Today Meeting Coverage - June 9, 2016 Category: Journals (General) Source Type: news
ASCO: Docetaxel Falls Short in High-Risk Prostate Cancer (CME/CE)
(MedPage Today) -- Adjuvant therapy didn't improve outcome (Source: MedPage Today Meeting Coverage)
Source: MedPage Today Meeting Coverage - June 8, 2016 Category: Journals (General) Source Type: news
Bayer and Orion Expand Clinical Development Program for BAY-1841788 (ODM-201) in Prostate Cancer
Phase III study to be initiated in metastatic hormone-sensitive prostate cancer assessing the androgen-receptor antagonist in combination with standard androgen deprivation therapy and the chemotherapy docetaxel
Start of patient enrollment expected towa... Biopharmaceuticals, OncologyBayer, Orion Corp, prostate cancer, ARASENS (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - June 3, 2016 Category: Pharmaceuticals Source Type: news
Genetic biomarker may predict nerve pain side effects associated with prostate cancer treatment
Taxanes are a group of drugs commonly used to treat cancers of the breast, lung, ovary, or prostate, but its use can be limited by significant side effects. Researchers report prostate cancer patients who have a variation in the VAC14 gene are more susceptible to a side effect called peripheral neuropathy when treated with the taxane docetaxel. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - May 13, 2016 Category: Science Source Type: news
Genetic biomarker may predict nerve pain side effects associated with prostate cancer treatment
(H. Lee Moffitt Cancer Center & Research Institute) Taxanes are a group of drugs commonly used to treat cancers of the breast, lung, ovary, or prostate, but its use can be limited by significant side effects. Researchers from Moffitt Cancer Center report prostate cancer patients who have a variation in the VAC14 gene are more susceptible to a side effect called peripheral neuropathy when treated with the taxane docetaxel. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - May 13, 2016 Category: Global & Universal Source Type: news
Prognostic Factors, Risk Stratification in CRPC on DocetaxelPrognostic Factors, Risk Stratification in CRPC on Docetaxel
Could certain prognostic factors help predict overall survival in castration-resistant prostate cancer patients treated with docetaxel? BMC Urology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - April 27, 2016 Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news
Company-led recall: Taxotere (Docetaxel) Concentrate for Solution for Infusion
, 80mg per 4ml
The Medicines and Healthcare products Regulatory Agency (MHRA) has issued a company-led recall for a spe (Source: Royal Pharmaceutical Society News)
Source: Royal Pharmaceutical Society News - April 20, 2016 Category: Drugs & Pharmacology Source Type: news
Tumor Marker Role in Metastatic Prostate CancerTumor Marker Role in Metastatic Prostate Cancer
A tumor marker in peripheral blood may help determine which men with metastatic castration-resistant prostate cancer (mCRPC) respond well to docetaxel and which will benefit from a different therapy, researchers from Spain suggests. Reuters Health Information (Source: Medscape Pathology Headlines)
Source: Medscape Pathology Headlines - March 21, 2016 Category: Pathology Tags: Hematology-Oncology News Source Type: news
